Cyclophosphamide
Demyelinating Autoimmune Diseases, Central Nervous System (CNS)
Indapta Therapeutics, INC.Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Demyelinating Autoimmune Diseases, Central Nervous System (CNS) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ocrevus Indapta Therapeutics, INC. | Phase 1 | CC |
Mesna Indapta Therapeutics, INC. | Phase 1 | CC |
Idp-023 Indapta Therapeutics, INC. | Phase 1 | CC |
Fludarabine Indapta Therapeutics, INC. | Phase 1 | CC |
Natalizumab Queen Mary University of London | Phase 2 | NR |
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →